Grant: Collaborative Health Research Projects (NSERC partnered)
McGill University
$218,863.00
Developing and clinically testing a learning algorithm that optimizes the performance of the artificial pancreas
EF 2015-16
Résumé
In healthy individuals, blood sugar levels are tightly controlled by two hormones: insulin and glucagon. Secretion of insulin, a vital hormone to reduce blood sugar, is lost in type 1 diabetes. Thus, type 1 diabetes patients are currently treated by
intensive insulin therapy through injections or insulin pump, but glucose control remains problematic and a big challenge for most patients.
Research is under steady progress by our group to develop an external artificial pancreas that automatically regulates glucose levels in patients with type 1 diabetes. The artificial pancreas is composed of three components: a continuous
glucose sensor (to measure glucose levels), infusion pumps (to infuse insulin and glucagon), and an intelligent dosing algorithm (to control insulin and glucagon delivery based on the readings of the sensor).
We have tested the artificial pancreas in several clinical trials in our clinical research facility and the results were promising. The artificial pancreas improved significantly glucose control and reduced the risk of hypoglycemia compared to conventional pump therapy. We are currently moving to longer and larger real-life studies at home.
The aim of this project is to improve the artificial pancreas so that it learns the insulin needs of the patients over time and adapts as the patient's insulin needs changes. We believe that this new algorithm will maintain and improve the performance of the system in face of slow changes in patients' insulin needs over weeks/months. We aim to test this new system in a computer simulation environment then clinically in 50 adolescents for 3 weeks.
The artificial has enormous potential to improve quality of life, improve health outcomes, prevent hypoglycemic events, provide confidence for physical activities and alleviate key aspect of the burden of diabetes for patients, families and health
care providers.
Programme
Collaborative Health Research Projects (NSERC partnered)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
336279
Name
Kearney Robert E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Natural Sciences and Engineering Research Council of Canada (NSERC)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Collaborative Health Research Projects - NSERC Partnered
Projecttitle
Developing and clinically testing a learning algorithm that optimizes the performance of the artificial pancreas
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$218,863
Cihrequipment2
$0
Programname2
Collaborative Health Research Projects (NSERC partnered)
Keyworddelim
Artificial Pancreas; Bayesian Estimation; Biomedical Engineering; Feedback Control; Type 1 Diabetes
Abstract
In healthy individuals, blood sugar levels are tightly controlled by two hormones: insulin and glucagon. Secretion of insulin, a vital hormone to reduce blood sugar, is lost in type 1 diabetes. Thus, type 1 diabetes patients are currently treated by
intensive insulin therapy through injections or insulin pump, but glucose control remains problematic and a big challenge for most patients.
Research is under steady progress by our group to develop an external artificial pancreas that automatically regulates glucose levels in patients with type 1 diabetes. The artificial pancreas is composed of three components: a continuous
glucose sensor (to measure glucose levels), infusion pumps (to infuse insulin and glucagon), and an intelligent dosing algorithm (to control insulin and glucagon delivery based on the readings of the sensor).
We have tested the artificial pancreas in several clinical trials in our clinical research facility and the results were promising. The artificial pancreas improved significantly glucose control and reduced the risk of hypoglycemia compared to conventional pump therapy. We are currently moving to longer and larger real-life studies at home.
The aim of this project is to improve the artificial pancreas so that it learns the insulin needs of the patients over time and adapts as the patient's insulin needs changes. We believe that this new algorithm will maintain and improve the performance of the system in face of slow changes in patients' insulin needs over weeks/months. We aim to test this new system in a computer simulation environment then clinically in 50 adolescents for 3 weeks.
The artificial has enormous potential to improve quality of life, improve health outcomes, prevent hypoglycemic events, provide confidence for physical activities and alleviate key aspect of the burden of diabetes for patients, families and health
care providers.
Competitiondate
201510
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Kearney, Robert E; Rabasa-Lhoret, Rémi
Approvedterm
3 ans 0 mois
Cihrcontribution2
Major Initiatives #2~ $218,863~ $0~